Last reviewed · How we verify
Egg based influenza vaccines
Egg-based influenza vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus strains grown in embryonated chicken eggs.
Egg-based influenza vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus strains grown in embryonated chicken eggs. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Egg based influenza vaccines |
|---|---|
| Sponsor | Henry M. Jackson Foundation for the Advancement of Military Medicine |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
These vaccines contain inactivated or attenuated influenza viruses that have been propagated in fertilized chicken eggs. The vaccine antigens trigger both humoral (antibody) and cell-mediated immune responses, enabling the body to recognize and neutralize circulating influenza viruses before infection occurs. This is a traditional vaccine platform that has been used for decades to provide seasonal protection against influenza.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fever
- Guillain-Barré syndrome
Key clinical trials
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Immunogenicity Trial of 3 Influenza Vaccines (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years (PHASE3)
- Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial (NA)
- Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (PHASE3)
- Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: